NovaBay Pharmaceuticals (NYSE:NBY) Announces Quarterly Earnings Results

NovaBay Pharmaceuticals (NYSE:NBY) posted its earnings results on Tuesday. The company reported ($0.95) earnings per share for the quarter, reports. The firm had revenue of $3.73 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 121.42% and a negative net margin of 65.46%.

NovaBay Pharmaceuticals Trading Down 5.9 %

Shares of NYSE:NBY traded down $0.01 during midday trading on Thursday, reaching $0.10. 1,981,271 shares of the company were exchanged, compared to its average volume of 3,657,216. NovaBay Pharmaceuticals has a fifty-two week low of $0.10 and a fifty-two week high of $1.95. The stock has a fifty day simple moving average of $0.15 and a two-hundred day simple moving average of $0.26.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of NovaBay Pharmaceuticals in a report on Friday, March 22nd. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NovaBay Pharmaceuticals stock. Armistice Capital LLC bought a new stake in NovaBay Pharmaceuticals, Inc. (NYSE:NBY) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned approximately 11.01% of NovaBay Pharmaceuticals at the end of the most recent quarter. 23.25% of the stock is owned by hedge funds and other institutional investors.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.